RecruitingPhase 1NCT06904066
Blood
Juvenile myelomonocytic leukemia
71
studies recruiting now
as of 7 Sept 2026
608
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
25 Nov 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT03383575
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
RecruitingPhase 1 / Phase 2NCT05849662
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RecruitingPhase 2NCT07249346
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 1 / Phase 2NCT06523556
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 71 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Juvenile myelomonocytic leukemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Juvenile myelomonocytic leukemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (RRAS, PTPN11, KRAS, NF1, NRAS, CBL).
Treatments being studied
1 approved treatment and 4 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Glasdegib
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 2Azacitidine (Azacitidine)
Phase 2Midostaurin (Rydapt)
Phase 1H3b-8800
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).